

FONAR Reports 12 Straight Quarters of Net Income From Operations and Six Straight Quarters of Profitability Greater Than $1.5 M
February 14, 2013 07:00 ET
FONAR Reports 12 Straight Quarters of Net Income From Operations and Six Straight Quarters of Profitability Greater Than $1.5 Million in 2nd Quarter Financial Results
MELVILLE, NY--(Marketwire - Feb 14, 2013) - FONAR Corporation (
Statement of Operations Items
- Income from operations for the six months and quarter ended December 31, 2012, was $3.6 million and $1.7 million, respectively, as compared to $3.7 million and $1.9 million respectively, for the same period one year earlier.
- Net income for the six months and quarter ended December 31, 2012, was $3.4 million and $1.6 million, respectively, as compared to $3.6 million and $1.8 million respectively, for the same period one year earlier.
- The basic net income per common share available to common stockholders, for the six months and quarter ended December 31, 2012 was $0.44 and $0.21, as compared to $0.50 and $0.25 for the six months and quarter ended December 31, 2011.
- The diluted net income per common share available to common stockholders, for the six months and quarter ended December 31, 2012 was $0.43 and $0.21, as compared to $0.49 and $0.24 for the six months and quarter ended December 31, 2011.
- Total revenue for the six months and quarter ended December 31, 2012, was $19.1 million and $9.6 million, respectively, as compared to $18.9 million and $9.3 million for the same period one year earlier.
- Total operating costs and expenses for the six months and quarter ended December 31, 2012, were $15.5 million and $7.9 million, respectively, as compared to $15.3 million and $7.4 million for the same period one year earlier.
- Revenue from the management and other fees segment, (HMCA management of the eleven FONAR UPRIGHT® Multi-Position™ MRI diagnostic imaging centers segment), for the six months and quarter ended December 31, 2012, was $11.5 million and $5.7 million respectively, as compared to $9.8 million and $4.9 million for the same period one year earlier. These are increases of 17% and 17% respectively.
- Revenue from the manufacturing and service segments for the FONAR UPRIGHT® Multi-Position™ MRI for the six months and quarter ended December 31, 2012, was $7.7 million and $3.9 million, respectively, as compared to $9.2 million and $4.4 million for the same period one year earlier.
- Research & development (R&D) and selling, general & administrative costs (S,G&A) were $2.7 million for the quarter ended December 31, 2012, as compared to $2.3 million for the quarter ended December 31, 2011.
Balance Sheet Items
- As of December 31, 2012 total current assets were $29.6 million, total assets were $36.8 million, total current liabilities were $21.4 million, and total long-term liabilities were $1.3 million.
- As of December 31, 2012, total cash and cash equivalents were $14.8 million.
- As of December 31, 2012, the total stockholders' equity was $14.1 million.
See the accompanying tables for more details.
Management Discussion
Raymond V. Damadian, M.D., president and chairman of FONAR said, "I am quite pleased with the Company's consistent progress since we redefined our corporate business strategy following the 2008 banking crisis. It is remarkable that we have had 1 1/2 years of net income and income from operations exceeding $1.5 million. Each quarter over the past three years we have consistently been profitable having earned income from operations. Our total assets have grown from $21.6 million at June 30, 2010 to $36.8 million most recently, shareholders' equity has climbed to over $14 million and our long-term liabilities are a low of $1.25 million."
"The eleven UPRIGHT® Multi-Position™ MRI centers that we manage continue to add scan volume," said Dr. Damadian. "In fact, for the three months ended December 31, 2012, the number of scans was 10,563 as compared to 10,332 scans over the same period one year earlier. This occurred in spite of the interruption caused by Hurricane Sandy which did cause several of our scanning centers to temporarily stop for a short period."
"Much of our success comes from the management team assembled that manages the imaging center management business. Key to their success though is the marketing strength of the FONAR STAND-UP® MRI (a.k.a. UPRIGHT® Multi-Position™ MRI)," said Dr. Damadian. "We have a considerable number of customer patients that tell us that they will never go and have a recumbent MRI again. Currently, we are managing eleven centers, all in New York and Florida."
"FONAR's UPRIGHT® MRI technology has opened a new frontier in medical imaging," said Dr. Damadian. "It is the power to make MRI motion pictures (cinés) of the cerebrospinal fluid (CSF) in the spinal canal as it flows into and out of the brain of the patient while Upright. These ciné MRIs of CSF flow in and out of the brain while the patient is Upright, are uniquely sensitive to the visualization of any impairments of CSF flow. This often leads to a better understanding of the problems with the cervical anatomy that might be contributing to the patient's symptoms."
"An example of the severe need of FONAR's unique UPRIGHT® Multi-Position™ MRI technology is FONAR's recent discovery of the potential adverse consequences of cervical spine malalignments. Such cervical spine degenerations or vertebral malalignments can obstruct the flow of cerebrospinal fluid (CSF), which in turn can generate increases of intracranial pressure (ICP) and CSF 'leakages' into the surrounding brain parenchyma. It has been proposed that CSF 'leakages', such as those shown to be joining the MS lesions in the MRI images of the MS patients studied, could be etiologic in the generation of multiple sclerosis (Damadian R.V., Chu D., '[ The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis ]', Physiol. Chem. Phys. & Med. NMR, September 20, 2011, 41:1-17). The report showed that the cervical anatomic abnormalities seen in these MS patients and the resulting CSF flow obstructions were significantly more severe with the patient in the vertical position (Table 2A, col. 10 & 11, Physiol. Chem. Phys. & Med. NMR, September 20, 2011 41:1-17) than with the patient in the recumbent position. Consequently, it is critical that any assessment of CSF flow impairment in the brain or spinal column must be assessed with the patient in the vertical position in order to determine the full extent of the CSF flow impairment, the extent of treatment needed and, most importantly, to achieve an accurate assessment post-treatment of the degree to which satisfactory CSF flow has been successfully restored. Accordingly," said Dr. Damadian, "we believe there now exists a genuine hope that if an MS patient can have their vertical position CSF flow and intracranial pressures (ICP) monitored and restored to normal, then there is also the prospect that the symptoms of this MS patient can be restored to normal."
About FONAR
FONAR (
[ UPRIGHT® ] and [ STAND-UP® ] are registered trademarks and [ The Inventor of MR Scanning™, ] Full Range of Motion™, [ Multi-Position™ ], Upright Radiology™, [ The Proof is in the Picture™ ], True Flow™, [ pMRI™ ], Spondylography™, [ Dynamic™ ], Spondylometry™, [ CSP™ ], and Landscape™, are trademarks of FONAR Corporation.
This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the [ company's filings with the Securities and Exchange Commission. ]
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
(000's OMITTED) | ||||||
ASSETS | ||||||
Current Assets: | December 31, 2012 (UNAUDITED) | June 30, 2012 | ||||
Cash and cash equivalents | $ | 14,760 | $ | 12,032 | ||
Accounts receivable - net | 4,920 | 5,095 | ||||
Accounts receivable - related party | 60 | - | ||||
Management and other fees receivable - net | 4,525 | 3,782 | ||||
Management and other fees receivable - related medical practices - net | 1,955 | 1,311 | ||||
Costs and estimated earnings in excess of billings on uncompleted contracts | 747 | 1,129 | ||||
Inventories | 2,239 | 2,195 | ||||
Current portion of notes receivable - net | 118 | 116 | ||||
Prepaid expenses and other current assets | 251 | 206 | ||||
Total Current Assets | 29,575 | 25,866 | ||||
Property and equipment - net | 2,927 | 3,173 | ||||
Notes receivable | 207 | 276 | ||||
Other intangible assets - net | 3,609 | 3,835 | ||||
Other assets | 487 | 465 | ||||
Total Assets | $ | 36,805 | $ | 33,615 | ||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(000's OMITTED, except per share data) | |||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
December 31, 2012 (UNAUDITED) | June 30, 2012 | ||||||
Current Liabilities: | |||||||
Current portion of long-term debt and capital Leases | $ | 1,483 | $ | 1,854 | |||
Accounts payable | 2,020 | 2,077 | |||||
Other current liabilities | 8,179 | 7,693 | |||||
Unearned revenue on service contracts | 5,536 | 5,475 | |||||
Unearned revenue on service contracts - related Party | 55 | - | |||||
Customer advances | 4,138 | 3,881 | |||||
Income tax payable | - | 100 | |||||
Total Current Liabilities | 21,411 | 21,080 | |||||
Long-Term Liabilities: | |||||||
Accounts payable, non current | 10 | 47 | |||||
Due to related medical practices | 229 | 229 | |||||
Long-term debt and capital leases, less current Portion | 634 | 777 | |||||
Other liabilities | 379 | 401 | |||||
Total Long-Term Liabilities | 1,252 | 1,454 | |||||
Total Liabilities | 22,663 | 22,534 | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(000's OMITTED, except per share data) | ||||||||
STOCKHOLDERS' EQUITY | ||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY (continued) STOCKHOLDERS' EQUITY: | December 31, 2012 (UNAUDITED) | June 30, 2012 | ||||||
Class A non-voting preferred stock $.0001 par value; 453,000 shares authorized at December 31, 2012 and June 30, 2012, 313,438 issued and outstanding at December 31, 2012 and June 30, 2012 | - | - | ||||||
Preferred stock $.001 par value; 567,000 shares authorized at December 31, 2012 and June 30, 2012, issued and outstanding - none | - | - | ||||||
Common Stock $.0001 par value; 8,500,000 shares authorized at December 31, 2012 and June 30, 2012, 5,942,905 and 5,912,905 issued at December 31, 2012 and June 30, 2012, respectively; 5,931,262 and 5,901,262 outstanding at December 31, 2012 and June 30, 2012, respectively | 1 | 1 | ||||||
Class B Common Stock (10 votes per share) $.0001 par value; 227,000 shares authorized at December 31, 2012 and June 30, 2012, 158 issued and outstanding at December 31, 2012 and June 30, 2012 | - | - | ||||||
Class C Common Stock (25 votes per share) $.0001 par value; 567,000 shares authorized at December 31, 2012 and June 30, 2012, 382,513 issued and outstanding at December 31, 2012 and June 30, 2012 | - | - | ||||||
Paid-in capital in excess of par value | 174,231 | 174,084 | ||||||
Accumulated other comprehensive loss | (20 | ) | (20 | ) | ||||
Accumulated deficit | (165,533 | ) | (168,334 | ) | ||||
Notes receivable from employee stockholders | (59 | ) | (71 | ) | ||||
Treasury stock, at cost - 11,643 shares of common stock | ||||||||
at December 31, 2012 and June 30, 2012 | (675 | ) | (675 | ) | ||||
Non controlling interests | 6,197 | 6,096 | ||||||
Total Stockholders' Equity | 14,142 | 11,081 | ||||||
Total Liabilities and Stockholders' Equity | $ | 36,805 | $ | 33,615 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) | |||||||||
(000's OMITTED, except per share data) | |||||||||
FOR THE THREE MONTHS ENDED DECEMBER 31, | |||||||||
REVENUES | 2012 | 2011 | |||||||
Product sales - net | $ | 1,080 | $ | 1,615 | |||||
Service and repair fees - net | 2,765 | 2,807 | |||||||
Service and repair fees - related parties - net | 28 | 27 | |||||||
Management and other fees - net | 3,775 | 3,308 | |||||||
Management and other fees - related medical practices - net | 1,965 | 1,571 | |||||||
Total Revenues - Net | 9,613 | 9,328 | |||||||
COSTS AND EXPENSES | |||||||||
Costs related to product sales | 904 | 1,171 | |||||||
Costs related to service and repair fees | 894 | 868 | |||||||
Costs related to service and repair fees - related parties | 9 | 9 | |||||||
Costs related to management and other fees | 2,235 | 1,887 | |||||||
Costs related to management and other fees - related medical practices | 852 | 901 | |||||||
Research and development | 320 | 293 | |||||||
Selling, general and administrative | 2,352 | 1,995 | |||||||
Provision for bad debts | 325 | 310 | |||||||
Total Costs and Expenses | 7,891 | 7,434 | |||||||
Income From Operations | 1,722 | 1,894 | |||||||
Interest Expense | (103 | ) | (124 | ) | |||||
Investment Income | 60 | 64 | |||||||
Other Expense | (4 | ) | (1 | ) | |||||
Income Before Provision for Income Taxes and Non Controlling Interests | 1,675 | 1,833 | |||||||
Provision for Income Taxes | 55 | 21 | |||||||
Net Income | 1,620 | 1,812 | |||||||
Net Income - Non Controlling Interests | 271 | 276 | |||||||
Net Income - Controlling Interests | $ | 1,349 | $ | 1,536 | |||||
Net Income Available to Common Stockholders | $ | 1,259 | $ | 1,432 | |||||
Net Income Available to Class A Non-Voting Preferred Stockholders | $ | 67 | $ | 78 | |||||
Net Income Available to Class C Common Stockholders | $ | 23 | $ | 26 | |||||
Basic Net Income Per Common Share Available to Common Stockholders | $ | 0.21 | $ | 0.25 | |||||
Diluted Net Income Per Common Share Available to Common Stockholders | $ | 0.21 | $ | 0.24 | |||||
Basic and Diluted Income Per Share-Common C | $ | 0.06 | $ | 0.07 | |||||
Weighted Average Basis Shares Outstanding | 5,926,262 | 5,728,528 | |||||||
Weighted Average Diluted Shares Outstanding | 6,053,766 | 5,856,032 | |||||||
Weighted Average Basic Shares Outstanding - Class C Common | 382,513 | 382,513 | |||||||
Weighted Average Diluted Shares Outstanding - Class C Common | 382,513 | 382,513 | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) | ||||||||||
(000's OMITTED, except per share data) | ||||||||||
FOR THE SIX MONTHS ENDED DECEMBER 31, | ||||||||||
REVENUES | 2012 | 2011 | ||||||||
Product sales - net | $ | 2,121 | $ | 3,391 | ||||||
Service and repair fees - net | 5,474 | 5,712 | ||||||||
Service and repair fees - related parties - net | 55 | 55 | ||||||||
Management and other fees - net | 7,544 | 6,637 | ||||||||
Management and other fees - related medical practices - net | 3,930 | 3,141 | ||||||||
Total Revenues - Net | 19,124 | 18,936 | ||||||||
COSTS AND EXPENSES | ||||||||||
Costs related to product sales | 1,959 | 2,646 | ||||||||
Costs related to service and repair fees | 1,760 | 1,682 | ||||||||
Costs related to service and repair fees - related parties | 18 | 16 | ||||||||
Costs related to management and other fees | 4,406 | 4,072 | ||||||||
Costs related to management and other fees - related medical practices | 1,669 | 1,720 | ||||||||
Research and development | 650 | 622 | ||||||||
Selling, general and administrative | 4,564 | 4,037 | ||||||||
Provision for bad debts | 500 | 485 | ||||||||
Total Costs and Expenses | 15,526 | 15,280 | ||||||||
Income From Operations | 3,598 | 3,656 | ||||||||
Interest Expense | (179 | ) | (231 | ) | ||||||
Investment Income | 120 | 126 | ||||||||
Other (Expense) Income | (13 | ) | 55 | |||||||
Income Before Provision for Income Taxes and Non Controlling Interests | 3,526 | 3,606 | ||||||||
Provision for Income Taxes | 127 | 21 | ||||||||
Net Income | 3,399 | 3,585 | ||||||||
Net Income - Non Controlling Interests | 598 | 535 | ||||||||
Net Income - Controlling Interests | $ | 2,801 | $ | 3,050 | ||||||
Net Income Available to Common Stockholders | $ | 2,616 | $ | 2,842 | ||||||
Net Income Available to Class A Non-voting Preferred Stockholders | $ | 138 | $ | 155 | ||||||
Net Income Available to Class C Common Stockholders | $ | 47 | $ | 53 | ||||||
Basic Net Income Per Common Share Available to Common Stockholders | $ | 0.44 | $ | 0.50 | ||||||
Diluted Net Income Per Common Share Available to Common Stockholders | $ | 0.43 | $ | 0.49 | ||||||
Basic and Diluted Income Per Share-Common C | $ | 0.12 | $ | 0.14 | ||||||
Weighted Average Basic Shares Outstanding | 5,913,762 | 5,698,645 | ||||||||
Weighted Average Diluted Shares Outstanding | 6,041,266 | 5,826,149 | ||||||||
Weighted Average Basic Shares Outstanding - Class C Common | 382,513 | 382,513 | ||||||||
Weighted Average Diluted Shares Outstanding - Class C Common | 382,513 | 382,513 | ||||||||